Abstract
The therapy of chronic inflammatory diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) has recently been enriched by the successful launch of the anti-cytokine biologicals Etanercept (tumor necrosis factor (TNF) receptor-p75 Fc fusion protein), Infliximab (chimeric anti-human TNF-α monoclonal antibody), Adalimumab (recombinant human anti-human TNF-α monoclonal antibody) and Anakinra (recombinant form of human interleukin 1β (IL-1) receptor antagonist) [1-3]. The success of these novel treatments has impressively demonstrated the clinical benefit that can be gained from therapeutic intervention in cytokine signalling, highlighting the central role of proinflammatory cytokine systems like IL-1β and TNF-α to be validated targets [4] However, all of the anti-cytokine biologicals available to date are proteins, and therefore suffering to a varying degree from the general disadvantages associated with protein drugs. Therefore, small molecular, orally active anti-cytokine agents, which target specific pathways of proinflammatory cytokines, would offer an attractive alternative to anti-cytokine biologicals. A number of molecular targets have been identified for the development of such small molecular agents but p38 mitogen-activated protein (MAP) kinase occupies a central role in the regulation of IL-1β and TNF-α signalling network at both the transcriptional and translational level [5, 6]. Since the mid-1990s, an immense number of inhibitors of p38 MAP kinase has been characterised in vitro, and to date several compounds have been advanced into clinical trials. This review will highlight the correlation between effective inhibition of p38 MAP kinase at the molecular target and cellular activity in functional assays of cytokine, particularly TNF-α and IL-1β production. SAR will be discussed regarding activity at the enzyme target, but also with regard to properties required for efficient in vitro and in vivo activity.
Keywords: N-Substituted Imidazoles, TNF alpha release, fused heterocycles, crystallisation, cytokine, anilinoquinazoline
Current Topics in Medicinal Chemistry
Title: New Approaches to the Treatment of Inflammatory Disorders Small Molecule inhibitors of p38 MAP Kinase
Volume: 6 Issue: 2
Author(s): Christian Peifer, Gerd Wagner and Stefan Laufer
Affiliation:
Keywords: N-Substituted Imidazoles, TNF alpha release, fused heterocycles, crystallisation, cytokine, anilinoquinazoline
Abstract: The therapy of chronic inflammatory diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) has recently been enriched by the successful launch of the anti-cytokine biologicals Etanercept (tumor necrosis factor (TNF) receptor-p75 Fc fusion protein), Infliximab (chimeric anti-human TNF-α monoclonal antibody), Adalimumab (recombinant human anti-human TNF-α monoclonal antibody) and Anakinra (recombinant form of human interleukin 1β (IL-1) receptor antagonist) [1-3]. The success of these novel treatments has impressively demonstrated the clinical benefit that can be gained from therapeutic intervention in cytokine signalling, highlighting the central role of proinflammatory cytokine systems like IL-1β and TNF-α to be validated targets [4] However, all of the anti-cytokine biologicals available to date are proteins, and therefore suffering to a varying degree from the general disadvantages associated with protein drugs. Therefore, small molecular, orally active anti-cytokine agents, which target specific pathways of proinflammatory cytokines, would offer an attractive alternative to anti-cytokine biologicals. A number of molecular targets have been identified for the development of such small molecular agents but p38 mitogen-activated protein (MAP) kinase occupies a central role in the regulation of IL-1β and TNF-α signalling network at both the transcriptional and translational level [5, 6]. Since the mid-1990s, an immense number of inhibitors of p38 MAP kinase has been characterised in vitro, and to date several compounds have been advanced into clinical trials. This review will highlight the correlation between effective inhibition of p38 MAP kinase at the molecular target and cellular activity in functional assays of cytokine, particularly TNF-α and IL-1β production. SAR will be discussed regarding activity at the enzyme target, but also with regard to properties required for efficient in vitro and in vivo activity.
Export Options
About this article
Cite this article as:
Peifer Christian, Wagner Gerd and Laufer Stefan, New Approaches to the Treatment of Inflammatory Disorders Small Molecule inhibitors of p38 MAP Kinase, Current Topics in Medicinal Chemistry 2006; 6 (2) . https://dx.doi.org/10.2174/156802606775270323
DOI https://dx.doi.org/10.2174/156802606775270323 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment
Current Vascular Pharmacology Otorhinolaryngological Manifestations in Sjogren Syndrome
Current Immunology Reviews (Discontinued) Editorial [Hot topic: Interstitial Lung Disease with Connective Tissue Diseases (Guest Editor: Eric Matteson)]
Current Rheumatology Reviews Rare Clinical Case of Cryopyrin-associated Periodic Syndrome Presented with Ankylosing Spondylitis: A Case Report
Current Rheumatology Reviews Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Current Genomics Editorial [Hot Topic: Stem Cell Based Therapy for Autoimmunity (Guest Editor: Frank Alderuccio)]
Current Stem Cell Research & Therapy Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Systemic Drug Delivery Systems for Bone Tissue Regeneration– A Mini Review
Current Pharmaceutical Design Leptin Plasma Levels in the General Population: Influence of Age, Gender, Body Weight and Medical History
Protein & Peptide Letters Management of Connective Tissue Interstitial Lung Disease
Current Respiratory Medicine Reviews Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Voltammetric Determination of Sinomenine in Biological Fluid Using a Glassy Carbon Electrode Modified by a Composite Film of Polycysteic Acid and Carbon Nanotubes
Combinatorial Chemistry & High Throughput Screening Ezetimibe and Vascular Endothelial Function
Current Vascular Pharmacology Editorial [Hot Topic: Proteome/Protein/Peptide in Molecular Medicine (Guest Editor: John M. Luk)
Protein & Peptide Letters Nutraceuticals and Bio-inspired Materials from Microalgae and their Future Perspectives
Current Topics in Medicinal Chemistry Advancements in Adjuvanticity of Bioactive Inorganic and Organic Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets The Relationship between Inflammatory and Oxidative Stress Biomarkers, Atherosclerosis and Rheumatic Diseases
Current Pharmaceutical Design Antiangiogenesis for Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy